News and blogs
FIRST CDKL5 CONFERENCE IN SPANISH On Saturday the 13th November 2021, the First CDKL5 Conference in Spanish was hosted and organised by CDKL5 Spain. During the conference, we had participants from the CDKL5 community which were Montserrat Minguell (President of CDKL5 Spain), Antonino Caridi (President of CDKL5 Alliance), MD. PhD Ángel Aledo (Neurologist and Neurophysiologist…
MAIN LESSONS FROM THE 2021 CDKL5 FORUM For the past seven years, the Loulou Foundation has hosted an annual meeting, the CDKL5 Forum, where scientists and drug developers working on CDKL5 Deficiency Disorder (CDD), together with representatives from patient organizations, meet to discuss the latest advances in the field. You can find written summaries from…
Loulou Foundation Announces Launch of Pre-Competitive Industry Collaboration for CDKL5 Deficiency Disorder Observational Study October 25, 2021 08:00 AM Eastern Daylight Time LONDON–(BUSINESS WIRE)–The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that seven biopharmaceutical industry partners together with the Loulou Foundation have formed…
Temporal manipulation of Cdkl5 reveals essential postdevelopmental functions and reversible CDKL5 deficiency disorder–related deficits CDKL5 deficiency disorder (CDD) is an early onset, neurodevelopmental syndrome associated with pathogenic variants in the X-linked gene encoding cyclin-dependent kinase-like 5 (CDKL5). CDKL5 has been implicated in neuronal synapse maturation, yet its postdevelopmental necessity and the reversibility of CDD-associated impairments…
Penn Study Suggests Genetic Disease CDKL5 Deficiency Disorder Could Be Treatable after Childhood Researchers find that restoring CDKL5 gene activity reverses many disease signs in young adult mice October 15, 2021 PHILADELPHIA— A devastating genetic disease called CDKL5 deficiency disorder (CDD), which strikes in early childhood, may be significantly treatable even in adulthood, a new…
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone We are excited to share that today Marinus Pharmaceuticals announced it signed an exclusive European market collaboration with Finland-based pharmaceutical company Orion Corporation. Marinus has received a $30 million upfront payment and is expected to receive around $115 million in R&D reimbursement and commercialization milestone payments for its compound…
